ASLAN Pharmaceuticals Limited (ASLN)

NASDAQ: ASLN · IEX Real-Time Price · USD
0.615
-0.025 (-3.89%)
At close: Mar 28, 2024, 4:00 PM
0.626
+0.011 (1.71%)
After-hours: Mar 28, 2024, 5:00 PM EDT

Company Description

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.

The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.

It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway.

Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.

ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals logo
Country Singapore
Founded 2010
IPO Date May 4, 2018
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.

Contact Details

Address:
83 Clemenceau Avenue, #12-03 Ue Square
Singapore, U0 239920
Singapore
Phone 65 6222 4235
Website aslanpharma.com

Stock Details

Ticker Symbol ASLN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001722926
CUSIP Number 04522R101
ISIN Number US04522R2004
SIC Code 2834

Key Executives

Name Position
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. Founder, Chief Executive Officer and Executive Director
Kiran Kumar Asarpota Chief Operating Officer and Head of Finance
Ben Goodger General Counsel
Stephen Doyle Chief Business Officer
Dr. Alexandre Kaoukhov M.D. Chief Medical Officer
Charlie Hsu Investor Relations Director
Chi-Chin Wang IR and Corporate Development Director

Latest SEC Filings

Date Type Title
Mar 28, 2024 D Notice of Exempt Offering of Securities
Mar 25, 2024 F-3 Filing
Mar 21, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 19, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Mar 14, 2024 424B5 Filing
Mar 13, 2024 6-K Report of foreign issuer
Mar 11, 2024 6-K Report of foreign issuer
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals